A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2
200
about 3 years
18+
16 sites in AZ, CO, FL +6
What this study is about
Researchers are testing zanidatamab, a medication, to see if it helps people with HER2-positive tumors. The trial will last for about 1081 days and involve approximately 200 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Zanidatamab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
zanidatamab
Primary: Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
Secondary: Disease control rate (DCR), as assessed by ICR, Disease control rate (DCR), as assessed by Investigator, Duration of Response (DOR) Per RECIST Version 1.1, as assessed by ICR, Duration of Response (DOR) Per RECIST Version 1.1, as assessed by Investigator, Number of Participants Discontinuing Study Treatment Due to TEAEs, Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) As Graded by NCI CTCAE Version 5.0, Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library, Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE)
Oncology